Does concurrent or adjuvant temozolomide improve survival in patients with 1p/19q non-codeleted anaplastic astrocytoma?
In PORTEC-4a, what molecular subgroup of endometrial cancer was treated with external beam radiation?
Does the use of FET-PET improve PFS when reirradiating recurrent GBM?
Answers
Adjuvant only for IDH-mutated, grade 3 astrocytomas. In CATNON, concurrent TMZ did not significantly improve survival, and for IDH-wt tumors neither concurrent nor adjuvant TMZ improved survival.
Those with p53abn, substantial LVI, or L1 cell adhesion molecule overexpression received pelvic radiation (14%). The rate of vaginal recurrence was deemed non-inferior with molecular-based adjuvant therapy, however the rate at 5 years was 4.5% compared to 1.6% with VBT across the board.
No. Compared with MRI-based target volumes, FET-PET didn’t improve PFS in the GLIAA trial. | QuadShot News
In PORTEC-4a, what molecular subgroup of endometrial cancer was treated with external beam radiation?
Does the use of FET-PET improve PFS when reirradiating recurrent GBM?
Answers
Adjuvant only for IDH-mutated, grade 3 astrocytomas. In CATNON, concurrent TMZ did not significantly improve survival, and for IDH-wt tumors neither concurrent nor adjuvant TMZ improved survival.
Those with p53abn, substantial LVI, or L1 cell adhesion molecule overexpression received pelvic radiation (14%). The rate of vaginal recurrence was deemed non-inferior with molecular-based adjuvant therapy, however the rate at 5 years was 4.5% compared to 1.6% with VBT across the board.
No. Compared with MRI-based target volumes, FET-PET didn’t improve PFS in the GLIAA trial. | QuadShot News